Author

Sebastián Garzón López

Observed names: S. Lopez, Sebastian Garzon Lopez

Observed institution: Hospital Universitario de Jerez

ORCID: 0000-0001-5655-8570

Observed ORCID: 0000-0001-5655-8570

OpenAlex ID: A5114036053

Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient.

2011 · José Barberán, Josep Mensa, et al. · PubMed · 14

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

2023 · Alberto Mussetti, Leyre Bento, et al. · Bone Marrow Transplantation · 13

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

2019 · Noemi Puig, Miguel T Hernández, et al. · Blood · 4

Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study

2023 · Laura Rosiñol Dachs, Carmen Montes Gaisán, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2

Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

2023 · Alberto Mussetti, Leyre Bento, et al. · Bone Marrow Transplantation · 1

Evolution of Age and Causes of Death in Patients with Multiple Myeloma in the Era of Novel Agents

2025 · Abel Rosado Rodriguez, Esther Ortega, et al. · Clinical Lymphoma Myeloma & Leukemia

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

2022 · Alberto Mussetti, Leyre Bento, et al. · Blood

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

2022 · Catarina Maia, Noemi Puig, et al. · Blood

Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study.

2019 · Rafael Ríos Tamayo, Mario Arnao Herraiz, et al. · Clinical Lymphoma Myeloma & Leukemia

Prescription Patterns and Outcomes of First-Line Therapy for Non-Transplant Eligible Multiple Myeloma Real-Life Patients According to Age: A Retrospective Analysis of the 2012-2016 Period

2019 · María José Cejalvo, Gabriela Bustamante, et al. · Clinical Lymphoma Myeloma & Leukemia

Renal Response in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM) and Severe Renal Impairment (RI): Interim Data From a Large Observational, Prospective Study

2015 · A. García-Guiñon, E. Morales, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 11

Citation count: 34

H-index: 3

I10-index: 2